Ph III trial of Nitec's Lodotra completes recruitment

16 March 2009

Nitec Pharma AG, a Swiss specialty drug developer, has finalized recruitment for the second pivotal Phase III trial of its lead product,  Lodotra (prednisone), its modified-release tablet developed to optimize  the efficacy of an orally-administered low dose of the steroid.

The CAPRA-2 study will evaluate the safety and efficacy of the agent in  the treatment of the signs and symptoms of rheumatoid arthritis, a  chronic, progressive and disabling autoimmune disorder.

The data will be used to file for US marketing approval together with  the data already available from the CAPRA-1 first pivotal Phase III  trial.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight